All In Biotech

Drug Trial Radar · NCT06102824

Organoid-based Functional Precision Therapy for Advanced Breast Cancer

Organoid-Guided Functional Precision Therapy Versus Treatment of Physician's Choice in Previously Treated HER2-negative Advanced Breast Cancer: A Phase II, Multicenter, Open-label, Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Nov 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 252 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

252

Planned (sponsor's estimate)

Start

Oct 1, 2024

Primary completion

Jun 30, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Guangdong Provincial People's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
First Affiliated Hospital, Sun Yat-Sen University; Sun Yat-sen University; Shantou Central Hospital
First posted
Oct 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II, multicenter, open-label, randomized controlled trial to compare the efficacy of organoid-guided treatment (OGT) to treatment of physician's choice (TPC) in previously treated, HER2-negative locally advanced or metastatic breast cancer. The study will seek to provide evidence for utilizing patient-derived organoid (PDO) model to personalize treatment strategies and inform clinical care for advanced breast cancer. Subjects randomized to the OGT group will undergo PDO generation and receive treatment dictated by subsequent PDO drug sensitivity screening. Subjects randomized to the TPC group will receive empirical therapy as selected by the treating physician.

Conditions

  • HER2-negative Breast Cancer
  • Advanced Breast Cancer

Interventions

  • Organoid-guided treatmentDrug

    The drugs predicted to be the most sensitive through organoid drug sensitivity screening. The drugs selected for sensitivity screening are from the following options: taxane, anthracycline, 5-fluorouracil, gemcitabine, vinorelbine, eribulin, utidelone, carboplatin, sacituzumab govitecan, and trastuzumab deruxtecan (for HER2-low patients).

  • TaxaneDrug

    Albumin-bound paclitaxel 260mg/m2, IV, q3w, or 100-125mg/m2, IV, days 1, 8, and 15, q4w OR Liposomal paclitaxel 175mg/m2, IV, q3w

  • CapecitabineDrug

    1000-1250mg/m2, PO, bid, days1-14, q3w

  • GemcitabineDrug

    800-1200mg/m2, IV, days 1, 8, q3w

  • VinorelbineDrug

    20-35mg/m2, IV, days 1 and 8, q3w

  • EribulinDrug

    1.4mg/m2, IV, days 1 and 8, q3w

  • AnthracyclineDrug

    Liposomal doxorubicin 50mg/m2, IV, q3w OR Liposomal doxorubicin 40mg/m2+Cyclophosphamide 600mg/m2, IV, q3w

  • CarboplatinDrug

    Carboplatin AUC 6, IV, q3w or q4w OR Carboplatin AUC 2+Gemcitabine 1000mg/m2, IV, days 1 and 8, q3w OR Carboplatin AUC 2+Albumin-bound paclitaxel 125mg/m2, IV, days 1 and 8, q3w

  • UtideloneDrug

    30mg/m2, IV, once per day on days 1-5, q3w

  • Trastuzumab deruxtecanDrug

    5.4mg/kg, IV, q3w

  • Sacituzumab govitecanDrug

    10mg/kg, IV, days 1 and 8, q3w

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survivalTime frame: Through study completion, with an expected average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.